A new era of medical innovation in the UK’s second city

Healthcare innovations can benefit from faster development, thanks to a collaborative pathway established between a leading university and an agile manufacturer and supplier.

A groundbreaking therapy has been taken from laboratory to market in record time, thanks to a template established by the University of Birmingham’s Healthcare Technologies Institute (HTI) and Birmingham Biotech. And that’s just the start: HTI researchers believe they now have a rapid route to commercialisation that can energise a new era of medical innovation and attract investment.

Therapies devised and developed by university research groups can face a battle to reach the public because of the licencing complexities and uncertainties that doom or delay many promising scientific products.

But the pandemic forced a shake-up of processes and created a climate of collaboration which HTI used to accelerate the development of its revolutionary NoriZite™ nasal spray, which combats airborne viruses, in partnership with private company Birmingham Biotech, winner of the Materials Innovation Award at the 2022 Med-Tech Innovation Awards.

INDEPENDENT 05 April 2023

Previous
Previous

Birmingham Biotech: Pioneering Solutions in the Biotech Landscape

Next
Next

NoriZite™ Nasal Spray blocks infection with Omicron SARS-CoV-2 variant in cell culture